SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-257254
Filing Date
2023-10-17
Accepted
2023-10-17 06:51:52
Documents
13
Period of Report
2023-10-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d560382d8k.htm   iXBRL 8-K 29290
2 EX-10.1 d560382dex101.htm EX-10.1 37660
  Complete submission text file 0001193125-23-257254.txt   195124

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amrx-20231016.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE amrx-20231016_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amrx-20231016_pre.xml EX-101.PRE 10811
7 EXTRACTED XBRL INSTANCE DOCUMENT d560382d8k_htm.xml XML 3239
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 231328432
SIC: 2834 Pharmaceutical Preparations